Stern R S, Thibodeau L A, Kleinerman R A, Parrish J A, Fitzpatrick T B
N Engl J Med. 1979 Apr 12;300(15):809-13. doi: 10.1056/NEJM197904123001501.
A 2.1-year prospective study of 1373 patients given oral 8-methoxypsoralen photochemotherapy for psoriasis revealed 30 patients with a total of 48 basal-cell and squamous-cell carcinomas. The observed incidence of cutaneous carcinoma was 2.63 (95 per cent confidence limits = 1.91 to 3.90) times that expected for an age, sex and geographically matched population. Relative risk to patients with history of ionizing radiation was 3.68 (99 per cent confidence limits, 2.42 to 8.69). Patients with a previous cutaneous carcinoma had a relative risk of 10.22 (99 per cent confidence limits, 4.78 to 37.08). A higher than expected proportion of squamous-cell carcinomas and an excess of squamous-cell carcinomas in areas not exposed to sun were seen. New patients with known histories of ionizing-radiation exposure or of skin tumors should be given 8-methyoxypsoralen photochemotherapy only if they understand the risks and have disabling psoriasis untreatable by other means.
一项对1373例接受口服8-甲氧基补骨脂素光化学疗法治疗银屑病患者的2.1年前瞻性研究显示,有30例患者共发生48例基底细胞癌和鳞状细胞癌。皮肤癌的观察发病率是年龄、性别和地理位置匹配人群预期发病率的2.63倍(95%置信区间=1.91至3.90)。有电离辐射史患者的相对风险为3.68(99%置信区间,2.42至8.69)。既往有皮肤癌的患者相对风险为10.22(99%置信区间,4.78至37.08)。观察到鳞状细胞癌的比例高于预期,且在未暴露于阳光的部位鳞状细胞癌过多。已知有电离辐射暴露史或皮肤肿瘤史的新患者,只有在他们了解风险且患有其他方法无法治疗的致残性银屑病时,才应给予8-甲氧基补骨脂素光化学疗法。